|
Gene: ZNF793 |
Gene summary for ZNF793 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF793 | Gene ID | 390927 |
Gene name | zinc finger protein 793 | |
Gene Alias | ZNF793 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6ZN11 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
390927 | ZNF793 | HCC1_Meng | Human | Liver | HCC | 4.30e-02 | -2.58e-02 | 0.0246 |
390927 | ZNF793 | HCC1 | Human | Liver | HCC | 1.43e-19 | 2.56e+00 | 0.5336 |
390927 | ZNF793 | HCC2 | Human | Liver | HCC | 6.05e-39 | 3.09e+00 | 0.5341 |
390927 | ZNF793 | HCC5 | Human | Liver | HCC | 7.97e-35 | 2.19e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ZNF793 | PERI | Stomach | CSG | HOXA-AS2,PM20D2,PPP3CB, etc. | 5.31e-02 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF793 | SNV | Missense_Mutation | novel | c.1093N>G | p.Lys365Glu | p.K365E | Q6ZN11 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ZNF793 | SNV | Missense_Mutation | rs759729464 | c.301N>A | p.Ala101Thr | p.A101T | Q6ZN11 | protein_coding | tolerated(0.78) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF793 | SNV | Missense_Mutation | c.272N>C | p.Arg91Thr | p.R91T | Q6ZN11 | protein_coding | tolerated(0.28) | benign(0.304) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF793 | SNV | Missense_Mutation | rs376403589 | c.562N>T | p.Arg188Trp | p.R188W | Q6ZN11 | protein_coding | tolerated(0.4) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF793 | SNV | Missense_Mutation | rs751883374 | c.1018C>T | p.Arg340Cys | p.R340C | Q6ZN11 | protein_coding | deleterious(0) | possibly_damaging(0.594) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ZNF793 | SNV | Missense_Mutation | rs200037315 | c.133G>A | p.Val45Ile | p.V45I | Q6ZN11 | protein_coding | tolerated(0.48) | benign(0.02) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF793 | SNV | Missense_Mutation | c.229N>T | p.His77Tyr | p.H77Y | Q6ZN11 | protein_coding | tolerated(0.37) | benign(0.042) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
ZNF793 | SNV | Missense_Mutation | c.1181N>T | p.Ala394Val | p.A394V | Q6ZN11 | protein_coding | deleterious(0.01) | benign(0.01) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZNF793 | SNV | Missense_Mutation | rs751578996 | c.251N>A | p.Arg84Gln | p.R84Q | Q6ZN11 | protein_coding | tolerated(0.77) | benign(0) | TCGA-AA-A01C-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ZNF793 | SNV | Missense_Mutation | c.919N>A | p.Gly307Arg | p.G307R | Q6ZN11 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-A01V-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |